logo

For the Inventor, By the Inventor

Boulogne-Billancourt, France

Ipsen Pharma S.a.s.


USPTO Granted Patents = 108



Trademarks = 34

Forward Citations = 518

Loading Chart...
Loading Chart...

150 inventors (with patents filed for the assignee):

goldMedal Zheng Xin Dong (46 out of 70 patents)

silverMedal Roland Cherif-Cheikh (12 out of 24 patents)

bronzeMedal Michael DeWitt Culler (12 out of 22 patents)

4.  Pierre-Etienne Chabrier De Lassauniere (10 out of 35 patents)

5.  Yeelana Shen (9 out of 11 patents)

6.  Michel Auguet (7 out of 21 patents)

7.  Jacques-Pierre Moreau (7 out of 43 patents)

8.  Christophe Thurieau (7 out of 31 patents)

9.  Serge Auvin (6 out of 35 patents)

10.  Daniel B Deoliveira (6 out of 6 patents)

11.  Jeanne Mary Comstock (6 out of 6 patents)

12.  Nathalie Mondoly (6 out of 8 patents)

13.  Dennis Bigg (6 out of 48 patents)

14.  Lydie Francine Poitout (6 out of 18 patents)

15.  Sun H Kim (6 out of 39 patents)


Core Competencies:
Pain Treatment
Osteoporosis Therapy
Protease Activity Assessment
Sustained Release Formulations
Somatostatin Analogs
Melanocortin Receptor Ligands
Ghrelin Analogs
Botulinum Neurotoxin Therapy
Dyskinesia Treatment
Gastrointestinal Motility
Insulin Sensitivity
Growth Hormone Releasing Peptides

108 patents:

1. 11753633 - Compositions and methods for treatment of pain (2023-09-12),
2. RE49444 - Method of treating osteoporosis comprising administration of PTHrP analog (2023-03-06),
3. 10787696 - System for the assessment of protease activity (2020-09-29),
4. 10543249 - Pharmaceutical composition for a sustained release of lanreotide (2020-01-28),
5. 10206968 - Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs (2019-02-19),
6. 9975880 - Imidazolidine-2,4-dione dervatives (2018-05-22),
7. 9918967 - Thiazole derivatives for treating dyskinesias caused by a chemical treatment (2018-03-20),
8. 9850280 - Melanocortin receptor ligands (2017-12-26),
9. 9827286 - Use of melanocortins to treat insulin sensitivity (2017-11-28),
10. 9777039 - Somatostatin analogs and dimers thereof (2017-10-03),
11. 9758549 - Melanocortin receptor ligands modified with hydantoin (2017-09-12),
12. 9731027 - Somatostatin-dopamine chimeric analogs (2017-08-15),
13. 9724397 - Sustained release formulations comprising very low molecular weight polymers (2017-08-08),
14. 9676752 - Imidazolidine-2,4-dione derivatives (2017-06-13),
15. 9603942 - Somatostatin-dopamine chimeric analogs (2017-03-28),
Ipsen Pharma S.A.S. is a global biopharmaceutical company focused on innovative solutions in oncology, neuroscience, and rare diseases. With a presence in more than 30 countries, Ipsen is dedicated to improving the lives of patients worldwide through scientific advancements and breakthrough therapies. They collaborate with healthcare professionals, patients, and partners to address unmet medical needs and advance patient care.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
108 Patents

#7 in Boulogne-Billancourt

#250 in France

#7,071 in the World

...
Boulogne-Billancourt, France

Ipsen Pharma S.a.s.

Forward Citations = 518

150 inventors:

goldMedal Zheng Xin Dong (46 out of 70 patents)

silverMedal Roland Cherif-Cheikh (12 out of 24 patents)

bronzeMedal Michael DeWitt Culler (12 out of 22 patents)

4.  Pierre-Etienne Chabrier De Lassauniere (10 out of 35 patents)

5.  Yeelana Shen (9 out of 11 patents)

Please report any incorrect information to support@idiyas.com
Loading…